The Leading eBooks Store Online
for Kindle Fire, Apple, Android, Nook, Kobo, PC, Mac, Sony Reader...
Most popular at the top
Web 2.0 and the Health Care Market: Health Care in the era of Social Media and the modern Internet
Diplomica Verlag 2010; US$ 37.73Hauptbeschreibung The present piece of research deals with the use of Web 2.0 applications within the health care market. When reviewing literature it became evident that up to now, research which has been conducted in this field is rather limited to single aspects of the topic. Comprehensive research investigating the topic as a whole could not... more...
Weiterentwicklung gesundheitspolitischer Reformkonzepte und deren Auswirkungen auf Gesundheitsdienstleister
BWV Berliner Wissenschafts-Verlag 2010; US$ 25.88Hauptbeschreibung Eine Analyse der gesetzlichen Rahmenbedingungen und der zukünftigen Weiterentwicklung der Gesundheitssysteme ist unumgänglich, um das Potential für Effizienz- und Qualitätsgewinne und die gegenwärtigen und zukünftigen Wettbewerbsbedingungen von Unternehmen auf dem Gesundheitsmarkt auszuloten. Thesengeleitet wird in mehreren wissenschaftlichen... more...
Strategisches Nachhaltigkeits-management in der pharmazeutischen Industrie
Springer Fachmedien 2007; US$ 84.99Gangland UK
John Blake Publishing 2009; US$ 6.78It was one of the most brutal killing crusades that Britain has ever seen. Two cruel brothers and their henchmen, synonymous with robbery, torture and bribery, presided over a murderous reign so brutal that Nottingham became forth in the UK's gun crime league. This is just one of the shocking true stories contained in this chilling book.Having delved... more...
Selling Sickness
Greystone Books 2008; US$ 22.95In this hard-hitting indictment of the pharmaceutical industry, Ray Moynihan and Allan Cassels show how drug companies are systematically using their dominating influence in the world of medical science, drug companies are working to widen the very boundaries that define illness. Mild problems are redefined as serious illness, and common complaints... more...
Pharmaceutical Marketing
Emerald Group Publishing Limited 2005; US$ 199.00Today, pharmaceutical companies are increasing their marketing budgets to advertise directly to the consumer. This spiraling effort has begun to attract the attention of both consumer advocacy groups, as well as the federal government (in the USA), in terms of taking a closer look at the effects of such advertising efforts. In July of 2005, the... more...
Risk-sharing in the Pharmaceutical Industry
Springer 2006; US$ 119.99Deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. This book applies the Nobel Prize awarded economic theory of Adverse Selection to analyze the topic theoretically. more...
Leading Pharmaceutical Innovation
Springer 2008; US$ 64.99Pharmaceutical giants have doubled their investments in drug development in the past only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. more...
Pharmaceutical Pricing Policies in a Global Market
Organisation for Economic Co-operation and Development 2008; US$ 70.00Pharmaceutical policy making raises particular challenges in reconciling key objectives for health policy, such as ensuring affordable access to the latest effective drugs, with other important policy considerations, such as providing support to a valuable national industry. Unusually among health policy issues, it also raises international considerations... more...
Innovation and Commercialisation in the Biopharmaceutical Industry
Edward Elgar Publishing 2010; US$ 40.00Addresses the implications for traditional pharmaceutical companies and biopharmaceutical start-ups of the realignment of the industry knowledge-base. This book shows that while traditional pharmaceutical companies have adjusted their business models to meet the challenges of biotechnology, biopharmaceutical start-ups have experienced problems. more...









